An interventional study of High-Concentration Compound Lactic Acid Bacteria Metabolite JK-5G and Placebo in Age 18 to 80 Years, Malignant Mechanical Bowel Obstruction Diagnosed Clinically/Radiologically, With Prior Abdominal Surgery for Relief and Hemodynamically Stable Within 24h Post-op, Per Investigator, sponsored by First Affiliated Hospital of Wenzhou Medical University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by First Affiliated Hospital of Wenzhou Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Objective: To evaluate the effects of the postbiotic preparation JK-5G on gastrointestinal function recovery (GI-2 time), gastrointestinal dysfunction, nutritional status, and safety in patients after surgery for malignant bowel obstruction.
Design: A randomized, double-blind, placebo-controlled, exploratory clinical trial. Patients are randomized 1:1 within 24 hours after surgery. After meeting criteria for initiating enteral intake, they receive either JK-5G or placebo (one sachet three times daily) for 10 consecutive days, and are followed up to postoperative day 30.
Study Population: Adult patients (18-80 years old) who undergo surgery for malignant mechanical bowel obstruction and are hemodynamically stable within 24 hours after surgery.
Sample Size: A total of 80 patients (40 in the postbiotic group and 40 in the placebo group). A blinded review of variability will be conducted after 40 patients have completed the study.
Primary Endpoint: Time from the end of surgery to GI-2 recovery, where GI-2 recovery is defined as the later of the following two events: first passage of stool/effective stoma output, and first tolerance of the target diet. Key secondary endpoints include daily I-FEED scores, incidence of prolonged postoperative ileus, achievement of nutritional targets, and safety events.
Statistics and Timeline: The primary analysis will use a stratified Cox model (intention-to-treat principle). The study is planned to be conducted from September 2026 to February 2028.
Project Title: A Randomized, Double-Blind, Placebo-Controlled Exploratory Clinical Trial of Highly Concentrated Compound Lactic Acid Bacteria Metabolites JK-5G for Promoting Gastrointestinal Function Recovery After Surgery for Malignant Bowel Obstruction Study Objective: To evaluate the effects of JK-5G on GI-2 recovery time, gastrointestinal dysfunction, nutritional recovery, and safety after surgery for malignant bowel obstruction Study Population: Adult patients who undergo surgery for malignant mechanical bowel obstruction and are haemodynamically stable within 24 hours after surgery Sample Size: Exploratory sample size of 80 cases (40 in the postbiotic group and 40 in the placebo group); a blinded variability review will be conducted after 40 patients have completed the study Inclusion Criteria: Aged 18-80 years; diagnosed with malignant-related mechanical bowel obstruction and have undergone surgery to relieve the obstruction; stable within 24 hours after surgery; informed consent signed Exclusion Criteria Residual mechanical obstruction or planned re-operation; short bowel syndrome/severe intestinal fistula; haemodynamic instability requiring continuous circulatory or respiratory support; allergy to the product; inability to discontinue other microecological preparations; pregnancy or lactation; concurrent participation in another interventional clinical trial; etc.
Trial Design: 1:1 randomised, double-blind, placebo-controlled within 24 hours after surgery; after reaching the criteria for initiating enteral intake, patients receive either JK-5G or placebo (one sachet three times daily) for 10 consecutive days; those who do not start the intervention continue to be followed up and are included in the ITT analysis Endpoint Measures: Primary endpoint: time from end of surgery to GI-2 recovery. Key secondary endpoints: daily I-FEED score, prolonged postoperative ileus, achievement of nutritional targets, and safety events. Other secondary endpoints include gastrointestinal recovery, hospitalisation, and 30-day outcomes Statistical Analysis: Primary analysis uses a stratified Cox model, reporting hazard ratios and 95% confidence intervals; ITT is the primary analysis, supported by per-protocol and safety sets; pre-specified sensitivity analyses for death, re-operation, and missing data Study Duration: Each patient is followed up to postoperative day 30; the overall study is planned from September 2026 to February 2028
First Affiliated Hospital of Wenzhou Medical University is the lead sponsor of 83 studies on the registry; 57 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet all of the following criteria to be enrolled:
Exclusion Criteria:
Subjects meeting any of the following criteria will not be enrolled:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: High-Concentration Compound Lactic Acid Bacteria Metabolite JK-5G
Drug: Placebo
Highly concentrated compound lactic acid bacteria metabolites JK-5G is mainly composed of inactivated lactic acid bacterial strains (such as Lactococcus lactis, approximately 21 species of Lactobacillus, etc.) and their bioactive metabolites. Its important components include short-chain fatty acids (SCFAs) and inactivated lactic acid bacteria.
The placebo is completely identical to JK-5G in appearance, color, particle size, taste, odor, packaging, labeling, and reconstitution characteristics. It does not contain lactic acid bacteria metabolites, live bacteria, inactivated bacterial cells, or any other ingredients with known microecological activity.
Time from surgery end to GI-2 recovery.
GI-2 is defined as the later of the following two events: (1) first passage of stool; in patients with a stoma, the first clinically meaningful spontaneous stoma output, excluding mere bloody fluid, irrigant, or mucus; and (2) first tolerance of the protocol-specified target diet, with no return to fasting/clear fluids only due to nausea, vomiting, or abdominal distension within the subsequent 24 hours, and no need for reinsertion of nasogastric decompression. The primary endpoint will be adjudicated by an outcome assessor who is independent of the clinical treatment decisions.
Time frame: From the end of surgery until GI-2 recovery, assessed up to 30 days after surgery
Daily I-FEED
Daily assessment from day 1 to 10 after surgery. An I-FEED score of 0-2 means normal recovery, 3-5 means gastrointestinal intolerance, and ≥6 means gastrointestinal dysfunction.
Time frame: Postoperative day 1 to 10
Prolonged Postoperative Ileus
Presence of at least 2 of the following 5 criteria on or after postoperative day 4, after excluding mechanical obstruction or other identifiable causes: ① nausea/vomiting within the past 24 hours; ② inability to tolerate oral/enteral feeding; ③ no passage of flatus or stool within the past 24 hours; ④ abdominal distension; ⑤ radiological findings supportive of ileus.
Time frame: On or after postoperative day 4
Nutritional Goal Attainment
Achievement of ≥60% of target energy intake on postoperative day 5. Additionally, the time to reaching ≥80% of target energy intake, daily energy/protein intake, and number of days on parenteral nutrition will be recorded.
Time frame: Postoperative day 5, up to 30 days
Safety Events
Adverse events (AEs) and serious adverse events (SAEs) during the treatment period, CTCAE grading, discontinuation of study product, as well as anastomotic leakage, intra-abdominal infection, surgical site infection, diarrhoea, abdominal pain, nausea/vomiting, and 30-day mortality.
Time frame: From baseline through 30 days after surgery
No study locations are listed for this record.
Start is estimated for Sep 2026; primary completion for Feb 2028, 17 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Wenzhou Medical University